Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Uncoupling the dopamine D1-D2 receptor complex: a novel target for antidepressant treatment.

Wong AH, Liu F.

Clin Pharmacol Ther. 2012 Feb;91(2):298-302. doi: 10.1038/clpt.2011.311.

PMID:
22205193
2.

Mechanism of action of clozapine in the context of dopamine D1-D2 receptor hetero-dimerization--a working hypothesis.

Dziedzicka-Wasylewska M, Faron-Górecka A, Górecki A, Kuśemider M.

Pharmacol Rep. 2008 Sep-Oct;60(5):581-7. Review.

3.

Emerging drugs for major depressive disorder.

Kennedy SH, Rizvi SJ.

Expert Opin Emerg Drugs. 2009 Sep;14(3):439-53. doi: 10.1517/14728210903107751. Review.

PMID:
19637989
4.

[Efficacy of atypical antipsychotics in depressive syndromes].

Quintin P, Thomas P.

Encephale. 2004 Nov-Dec;30(6):583-9. Review. French.

PMID:
15738862
5.

Current investigational drugs for major depression.

Kulkarni SK, Dhir A.

Expert Opin Investig Drugs. 2009 Jun;18(6):767-88. doi: 10.1517/13543780902880850 . Review.

PMID:
19426122
6.

Dopamine D2-like receptors and the antidepressant response.

Gershon AA, Vishne T, Grunhaus L.

Biol Psychiatry. 2007 Jan 15;61(2):145-53. Review.

PMID:
16934770
7.

[Mechanism of action of antidepressants and therapeutic perspectives].

Bourin M, David DJ, Jolliet P, Gardier A.

Therapie. 2002 Jul-Aug;57(4):385-96. Review. French.

PMID:
12422559
8.

Metabotropic glutamate receptors in the control of mood disorders.

Witkin JM, Marek GJ, Johnson BG, Schoepp DD.

CNS Neurol Disord Drug Targets. 2007 Apr;6(2):87-100. Review.

PMID:
17430147
9.

Galanin receptor antagonists : a potential novel pharmacological treatment for mood disorders.

Ogren SO, Kuteeva E, Hökfelt T, Kehr J.

CNS Drugs. 2006;20(8):633-54. Review.

PMID:
16863269
10.

Receptor targets for antidepressant therapy in bipolar disorder: an overview.

Fountoulakis KN, Kelsoe JR, Akiskal H.

J Affect Disord. 2012 May;138(3):222-38. doi: 10.1016/j.jad.2011.04.043. Review.

PMID:
21601292
11.

Effects of antidepressants on uptake and receptor systems in the brain.

Fuller RW, Wong DT.

Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(5-6):485-90. Review.

PMID:
2868490
12.

Relationship of neurotransmitters to the symptoms of major depressive disorder.

Nutt DJ.

J Clin Psychiatry. 2008;69 Suppl E1:4-7. Review.

13.

Functional alterations in dopamine systems assessed using drug discrimination procedures.

Cory-Slechta DA, Widzowski DV, Pokora MJ.

Neurotoxicology. 1993 Summer-Fall;14(2-3):105-14. Review.

PMID:
8247385
15.

Targeting the dopamine D2 receptor in schizophrenia.

Seeman P.

Expert Opin Ther Targets. 2006 Aug;10(4):515-31. Review.

PMID:
16848689
16.

Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression.

Trivedi MH, Hollander E, Nutt D, Blier P.

J Clin Psychiatry. 2008 Feb;69(2):246-58. Review.

PMID:
18363453
17.

Involvement of prolactin and somatostatin in depression and the mechanism of action of antidepressant drugs.

Faron-Górecka A, Kuśmider M, Solich J, Kolasa M, Szafran K, Zurawek D, Pabian P, Dziedzicka-Wasylewska M.

Pharmacol Rep. 2013;65(6):1640-6. Review.

18.

Fresh approaches to antidepressant drug discovery.

Anacker C.

Expert Opin Drug Discov. 2014 Apr;9(4):407-21. doi: 10.1517/17460441.2014.892071. Review.

PMID:
24588262
19.

Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism.

Stahl SM.

Int J Neuropsychopharmacol. 2007 Oct;10(5):575-8. Review. No abstract available.

PMID:
17681087
20.

Epigenetic effect of chronic stress on dopamine signaling and depression.

Moriam S, Sobhani ME.

Genet Epigenet. 2013 Feb 10;5:11-6. doi: 10.4137/GEG.S11016. Review.

Items per page

Supplemental Content

Support Center